
Empresas de ponta deve revisitar sua estratégia de inovação, pegada e infraestrutura; processos de liderança e talento; modelos de tomada de decisão; abordagens de parceria; e outros aspectos do modelo antigo. - Christophe Durand
EDUCAÇÃO
- MSC, Gerenciamento de Engenharia, Universidade de Stanford
- Dipl.-ing., École Polytechnique
Christophe Durand joined the Paris office of The Boston Consulting Group in 1998 and moved to the New York office three years later. He is a core member of the Health Care practice, with deep industry experience in medtech and biopharma generics. He is also a global topic leader in growth and innovation in medtech.
Christophe tem experiência direta em vários segmentos de ciências da Medtech e da vida, incluindo grandes equipamentos, suprimentos clínicos, ortopedia, cirurgia cardíaca, geral, cuidados críticos e medicina de emergência. Vivo
In 2010, Christophe led BCG's medtech R&D benchmark of 30 participants across sectors and coauthored the resulting article in In Vivo. Vídeos
Christophe was a key member of the team that managed the integration of Mylan and Merck Generics in 2007 and 2008. He has also been involved in a number of other topics (such as strategy for injectables, commercial effectiveness, and general and administrative optimization) with several generics clients.